Zacks Research Brokers Lift Earnings Estimates for Glaukos

Glaukos logo with Healthcare background
Image from MarketBeat Media, LLC.

Glaukos Corporation (NYSE:GKOS - Free Report) - Analysts at Zacks Research boosted their FY2026 EPS estimates for shares of Glaukos in a research report issued on Wednesday, November 18th. Zacks Research analyst Team now forecasts that the medical instruments supplier will earn $0.42 per share for the year, up from their prior estimate of ($0.43). Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Glaukos' current full-year earnings is $0.50 per share. Zacks Research also issued estimates for Glaukos' Q4 2026 earnings at $0.27 EPS, Q1 2027 earnings at $0.09 EPS, Q2 2027 earnings at $0.17 EPS, Q3 2027 earnings at $0.33 EPS, Q4 2027 earnings at $0.65 EPS, FY2027 earnings at $1.24 EPS, Q3 2028 earnings at $0.58 EPS and FY2028 earnings at $2.24 EPS.

Glaukos (NYSE:GKOS - Get Free Report) last announced its quarterly earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 EPS for the quarter, beating the consensus estimate of ($0.10) by $0.57. The firm had revenue of $211.03 million during the quarter, compared to the consensus estimate of $168.04 million. Glaukos had a negative net margin of 24.60% and a negative return on equity of 0.97%. The business's quarterly revenue was up 58.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.16) EPS.

A number of other brokerages have also weighed in on GKOS. Wall Street Zen upgraded Glaukos from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 7th. Citigroup boosted their price objective on Glaukos from $225.00 to $247.00 and gave the stock a "buy" rating in a report on Thursday, October 29th. UBS Group started coverage on Glaukos in a report on Tuesday, July 28th. They set a "neutral" rating and a $150.00 price objective for the company. JPMorgan Chase & Co. lifted their target price on shares of Glaukos from $200.00 to $240.00 and gave the company an "overweight" rating in a research report on Thursday, October 29th. Finally, Piper Sandler reissued an "overweight" rating and issued a $240.00 price target (up from $195.00) on shares of Glaukos in a research note on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Glaukos has an average rating of "Moderate Buy" and a consensus price target of $218.00.

Read Our Latest Stock Analysis on Glaukos

Glaukos Trading Up 2.2%

NYSE:GKOS opened at $238.17 on Friday. Glaukos has a 52-week low of $93.78 and a 52-week high of $255.18. The stock has a fifty day moving average of $189.52 and a 200 day moving average of $149.49. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.57 and a quick ratio of 4.09.

Insider Activity at Glaukos

In other Glaukos news, Director Gilbert Kliman sold 2,500 shares of the stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $253.00, for a total transaction of $632,500.00. Following the transaction, the director directly owned 37,406 shares in the company, valued at $9,463,718. This trade represents a 6.26% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Joseph E. Gilliam sold 861 shares of the stock in a transaction that occurred on Monday, November 16th. The shares were sold at an average price of $250.00, for a total transaction of $215,250.00. Following the transaction, the chief operating officer owned 71,602 shares in the company, valued at $17,900,500. The trade was a 1.19% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 48,278 shares of company stock valued at $11,911,705. 5.90% of the stock is owned by insiders.

Institutional Trading of Glaukos

Several hedge funds and other institutional investors have recently bought and sold shares of GKOS. Kestra Advisory Services LLC purchased a new stake in Glaukos during the 3rd quarter valued at $200,000. EWA LLC purchased a new position in shares of Glaukos in the third quarter valued at about $218,000. Algert Global LLC increased its position in shares of Glaukos by 43.7% in the third quarter. Algert Global LLC now owns 44,361 shares of the medical instruments supplier's stock valued at $7,284,000 after acquiring an additional 13,490 shares during the period. Castleark Management LLC bought a new position in shares of Glaukos during the third quarter valued at about $7,812,000. Finally, Virtu Financial LLC bought a new position in shares of Glaukos during the third quarter valued at about $338,000. Institutional investors own 99.04% of the company's stock.

More Glaukos News

Investors following GKOS have been watching these news items:

  • Positive Sentiment: Zacks Research raised its Q1 2028 EPS estimate to $0.27 from $0.18 and its Q2 2028 estimate to $0.45 from $0.37, while maintaining a “Strong Buy” rating. Higher forecasts may reinforce expectations for continued earnings growth.
  • Positive Sentiment: A recent report attributed Glaukos’ 48.2% rally since the end of September to strong third-quarter results, increased sales guidance, growth in Epioxa and iDose TR, and positive clinical data. What Drove Glaukos Stock's 48% Rally Since the End of September?
  • Positive Sentiment: A cash-flow valuation analysis suggested GKOS could be 33% below fair value, a potentially supportive view for investors assessing the stock’s longer-term upside. Glaukos Stock May Be 33% Below Fair Value On Cash Flow

About Glaukos

(Get Free Report)

Glaukos Corporation is an ophthalmic medical technology company that develops and commercializes treatments for glaucoma and other eye disorders. Its portfolio includes minimally invasive glaucoma surgery (MIGS) devices, such as the iStent family, and iDose TR, an implant designed to deliver glaucoma medication inside the eye over an extended period. The company also offers products for corneal disorders, including technology used in corneal cross-linking procedures to treat keratoconus and other conditions that weaken the cornea.

See Also

Earnings History and Estimates for Glaukos (NYSE:GKOS)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Glaukos Right Now?

Before you consider Glaukos, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Glaukos wasn't on the list.

While Glaukos currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Could Lead the Next Market Boom Cover

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines